Efficacy and feasibility of the RADA16 self-assembling peptide, PuraStat® for haemostasis in laparoscopic gynaecological surgery: A pilot study

other OA: closed public-domain-us
View on PubMed View at publisher

Abstract

Bleeding after laparoscopic gynaecological surgery remains a potential complication. We assessed RADA16 (PuraStat®), a topical self-assembling peptide haemostatic agent, in a pilot study of 46 women undergoing laparoscopic gynaecological surgery. The primary outcome was intraoperative haemostatic efficacy for resection site bleeding. Haemostasis was achieved in all intraoperative bleeding situations (40/40 participants: 100%) with no clinically significant surgical bed bleeding or complications. Mean volume and time required to achieve haemostasis were 6 mL and 14 sec, respectively. This study suggests that PuraStat® is a safe, effective haemostatic agent in laparoscopic gynaecological surgery. Randomised controlled trials are warranted to confirm these findings.

My notes (saved in your browser only)

MeSH descriptors

Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies Feasibility Studies

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-07-19T06:13:33.711413+00:00
pubmed
last seen: 2026-07-19T06:11:36.333831+00:00
unpaywall
last seen: 2026-05-15T02:00:00.661756+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine